What is the current valuation of the UK Anti Hypertensive Drugs Market?

The market valuation was 1.93 USD Billion in 2024. Read More

What is the projected market size for the UK Anti Hypertensive Drugs Market by 2035?

The market is expected to reach 2.97 USD Billion by 2035. Read More

What is the expected CAGR for the UK Anti Hypertensive Drugs Market during the forecast period?

The anticipated CAGR for the market from 2025 to 2035 is 3.99%. Read More

Which drug classes dominate the UK Anti Hypertensive Drugs Market?

Key drug classes include Angiotensin Converting Enzyme Inhibitors and Beta Blockers, with valuations of 0.68 and 0.64 USD Billion respectively. Read More

How does the market perform across different administration routes?

The Oral administration route leads with a valuation of 1.45 USD Billion, followed by Intravenous at 0.65 USD Billion. Read More

What are the primary patient demographics for anti hypertensive drugs in the UK?

Adults represent a significant segment, with a market valuation of 1.25 USD Billion. Read More

What therapeutic indications are most prevalent in the UK Anti Hypertensive Drugs Market?

Hypertension is the leading indication, with a market size of 1.15 USD Billion. Read More

Who are the key players in the UK Anti Hypertensive Drugs Market?

Prominent players include AstraZeneca, Novartis, and Pfizer, among others. Read More

What is the market trend for diuretics in the UK?

Diuretics are projected to grow from 0.30 USD Billion to 0.45 USD Billion by 2035. Read More

How does the market for pediatric anti hypertensive drugs compare to other demographics?

The pediatric segment is smaller, with a valuation expected to rise from 0.15 USD Billion to 0.25 USD Billion by 2035. Read More

UK Anti Hypertensive Drugs Market

ID: MRFR/HC/54821-HCR

200 Pages

Satyendra Maurya

Last Updated: May 12, 2026

UK Antihypertensive Drugs Market UK Antihypertensive Drugs Market Research Report: By Drug Class (Diuretics, ACE Inhibitors, Beta Blockers, Calcium Channel Blockers, Angiotensin II Receptor Antagonists), By Administration Route (Oral, Injectable, Transdermal), By Indication (Essential Hypertension, Secondary Hypertension, Hypertensive Crisis) andBy Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)- Forecast to 2035

UK Anti Hypertensive Drugs Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 UK Anti Hypertensive Drugs Market, BY Drug Class (USD Billion) | |
  1. 4.1.1 Angiotensin Converting Enzyme Inhibitors | |
  2. 4.1.2 Angiotensin II Receptor Blockers | |
  3. 4.1.3 Calcium Channel Blockers | |
  4. 4.1.4 Diuretics | |
  5. 4.1.5 Beta Blockers |
2. 4.2 UK Anti Hypertensive Drugs Market, BY Administration Route (USD Billion) | |
  1. 4.2.1 Oral | |
  2. 4.2.2 Intravenous | |
  3. 4.2.3 Subcutaneous | |
  4. 4.2.4 Transdermal |
3. 4.3 UK Anti Hypertensive Drugs Market, BY Patient Demographics (USD Billion) | |
  1. 4.3.1 Elderly | |
  2. 4.3.2 Adults | |
  3. 4.3.3 Pediatric | |
  4. 4.3.4 Pregnant Women |
4. 4.4 UK Anti Hypertensive Drugs Market, BY Therapeutic Indication (USD Billion) | |
  1. 4.4.1 Hypertension | |
  2. 4.4.2 Heart Failure | |
  3. 4.4.3 Chronic Kidney Disease | |
  4. 4.4.4 Post-Myocardial Infarction 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the UK Anti Hypertensive Drugs Market | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the UK Anti Hypertensive Drugs Market | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 AstraZeneca (GB) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Novartis (CH) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Pfizer (US) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Boehringer Ingelheim (DE) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Sanofi (FR) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Merck & Co. (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 GlaxoSmithKline (GB) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Bristol-Myers Squibb (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Johnson & Johnson (US) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 UK MARKET ANALYSIS BY DRUG CLASS |
6. 6.3 UK MARKET ANALYSIS BY ADMINISTRATION ROUTE |
7. 6.4 UK MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
8. 6.5 UK MARKET ANALYSIS BY THERAPEUTIC INDICATION |
9. 6.6 KEY BUYING CRITERIA OF UK ANTI HYPERTENSIVE DRUGS MARKET |
10. 6.7 RESEARCH PROCESS OF MRFR |
11. 6.8 DRO ANALYSIS OF UK ANTI HYPERTENSIVE DRUGS MARKET |
12. 6.9 DRIVERS IMPACT ANALYSIS: UK ANTI HYPERTENSIVE DRUGS MARKET |
13. 6.10 RESTRAINTS IMPACT ANALYSIS: UK ANTI HYPERTENSIVE DRUGS MARKET |
14. 6.11 SUPPLY / VALUE CHAIN: UK ANTI HYPERTENSIVE DRUGS MARKET |
15. 6.12 UK ANTI HYPERTENSIVE DRUGS MARKET, BY DRUG CLASS, 2024 (% SHARE) |
16. 6.13 UK ANTI HYPERTENSIVE DRUGS MARKET, BY DRUG CLASS, 2024 TO 2035 (USD Billion) |
17. 6.14 UK ANTI HYPERTENSIVE DRUGS MARKET, BY ADMINISTRATION ROUTE, 2024 (% SHARE) |
18. 6.15 UK ANTI HYPERTENSIVE DRUGS MARKET, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion) |
19. 6.16 UK ANTI HYPERTENSIVE DRUGS MARKET, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE) |
20. 6.17 UK ANTI HYPERTENSIVE DRUGS MARKET, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Billion) |
21. 6.18 UK ANTI HYPERTENSIVE DRUGS MARKET, BY THERAPEUTIC INDICATION, 2024 (% SHARE) |
22. 6.19 UK ANTI HYPERTENSIVE DRUGS MARKET, BY THERAPEUTIC INDICATION, 2024 TO 2035 (USD Billion) |
23. 6.20 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
24. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
25. 7.2 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY DRUG CLASS, 2026-2035 (USD Billion) | |
  2. 7.2.2 BY ADMINISTRATION ROUTE, 2026-2035 (USD Billion) | |
  3. 7.2.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Billion) | |
  4. 7.2.4 BY THERAPEUTIC INDICATION, 2026-2035 (USD Billion) |
26. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.3.1 |
27. 7.4 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

UK Anti Hypertensive Drugs Market Segmentation

UK Anti Hypertensive Drugs Market By Drug Class (USD Billion, 2022-2035)

Angiotensin Converting Enzyme Inhibitors
Angiotensin II Receptor Blockers
Calcium Channel Blockers
Diuretics
Beta Blockers

UK Anti Hypertensive Drugs Market By Administration Route (USD Billion, 2022-2035)

Oral
Intravenous
Subcutaneous
Transdermal

UK Anti Hypertensive Drugs Market By Patient Demographics (USD Billion, 2022-2035)

Elderly
Adults
Pediatric
Pregnant Women

UK Anti Hypertensive Drugs Market By Therapeutic Indication (USD Billion, 2022-2035)

Hypertension
Heart Failure
Chronic Kidney Disease
Post-Myocardial Infarction

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035